BRAF and melanoma: The selective BRAF kinase inhibitors (Vemurafenib and dabrafenib) are effective in BRAF mutant melanoma; MEK inhibitors (trametinib and cobimetinib) show efficacy against both BRAF- and KRAS/NRAS-driven tumors; KIT inhibitors (imatinib, dasatinib, sunitinib and nilotinib) have demonstrated clinical responses in melanoma arising from acral, mucosal, and chronic sun-damaged cutaneous sites; and additionally, there are novel therapeutic monoclonal antibodies targeted against immunosuppressive molecules such as CTLA4, PD-1 and PD-L1.